INSM

Insmed Incorporated NMS · INSM

$108.32 +0.86 (+0.80%)

Neutral · -0.05σ

+ Compare Open in Sniper

Mkt cap $23.5B

P/E —

Day $105.20 – $110.58

52wk $90.39 – $167.37

Avg vol 3.8M

Beta 0.78

Div yld —

Next earnings 2026-08-06

Quick read

Plain English

Insmed Incorporated develops and commercializes therapies for patients with serious and rare diseases in the United States, Europe, Japan, and internationally.

INSM last traded at $108.32, up 0.8% on the day; that's in the lower part of its 52-week range ($90.39–$167.37). Right now it's trading close to its recent average, with no strong stretch in either direction.

The next scheduled earnings report (2026-08-06) is the biggest known catalyst on the calendar, and day to day, watch whether it holds above or slips below its recent average.

A plain-English snapshot built from the data on this page — not investment advice. Always do your own research.

Today's read

Grading desk →

above KC1 lower, -0.06 ATR from EMA21 — no notable pattern

Long —

score 12 · tech 12 / 80 · support 0 / 20

above KC1 lower, -0.06 ATR from EMA21 · no notable pattern

· RSI cushion turning up (50)

How this grade was earned

total 12 pts

Cycle position 6

Momentum 3

Market fit 3

Each bar shows how many points that factor added. The more points — and the more factors that agree — the higher the letter grade.

Short —

score 12 · tech 12 / 80 · support 0 / 20

below KC1 upper, -0.06 ATR from EMA21 · no notable pattern

· Aligned with weak downtrend

How this grade was earned

total 12 pts

Cycle position 6

Market fit 6

Each bar shows how many points that factor added. The more points — and the more factors that agree — the higher the letter grade.

132-Day Trend Zones

Full chart →

21 EMA +1 ATR +2 ATR −2 ATR

—

O — H — L — C —

— —

Valuation & accounting

Valuation desk →

The model's verdict is “Unknown” and accounting quality screens as Weak. Model estimates only — do your own due diligence.

Fair-value range

$8.39 – $8.39

Verdict

Unknown

Accounting quality Weak

✓ More cash than debt
✓ Quick ratio 2.91 (antifragile)
✓ Current ratio 3.83 (antifragile)
✓ Goodwill 6% of assets (organic growth)

⚠ Debt/equity 2.06 (fragile)
⚠ Negative retained earnings
⚠ Receivables growing faster than revenue
⚠ Stock comp 25% of revenue (heavy dilution)

Key statistics

All statistics →

INSM is a $23.5 billion company.

Mkt cap $23.5B

P/E ttm —

Fwd P/E 814.4

Beta 0.78

Day range $105.20 – $110.58

52w range $90.39 – $167.37

Avg vol 3.8M

RSI(2) 37.6

ROE -294.5%

Net mgn -144.4%

FCF mgn -74.0%

Debt/Eq 1.05

Div yld —

Sector Healthcare

Industry Biotechnology

Next earn 2026-08-06

52-week range · today's price

$90.39$167.37

More on INSM

Options idea

See more →

CALL $110 2026-08-21

$8.20

PUT $110 2026-08-21

$9.18

Earnings

See more →

Last reported: 2026-05-07
EPS (act / est): -0.76 / -1.00
Surprise: +23.9%
Next report: 2026-08-06

About

Insmed Incorporated develops and commercializes therapies for patients with serious and rare diseases in the United States, Europe, Japan, and internationally. The company offers ARIKAYCE for the treatment of refractory nontuberculous mycobacterial lung infections, as well as is in phase 3 clinical trial for the treatment of mycobacterium avium complex lung disease as part of a…